QGEN
NYSEQiagen N.V.
Website
News25/Ratings12
News · 26 weeks30-50%
2025-10-262026-04-19
Mix1590d
- Dividends5(33%)
- Other5(33%)
- Analyst2(13%)
- Leadership1(7%)
- Earnings1(7%)
- SEC Filings1(7%)
Latest news
25 items- PRQIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve as a foundation for lab workflows, enabling standardized nucleic acid extraction for clinical and translational research Introduction of the QIAGEN Discovery Platform, an AI-grounding solution to power downstream AI applications and support drug discovery for research purposes QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrat
- PRQIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx PanelQIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making Launch marks QIAGEN's expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The lau
- ANALYSTQiagen downgraded by Barclays with a new price targetBarclays downgraded Qiagen from Overweight to Equal Weight and set a new price target of $44.00
- PRQiagen Announces Form 20-F Annual Report Filing for 2025 ResultsQIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to ir@qiagen.com. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and a
- SECSEC Form 20-F filed by Qiagen N.V.20-F - QIAGEN N.V. (0001015820) (Filer)
- SECSEC Form IRANNOTICE filed by Qiagen N.V.IRANNOTICE - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB PreventionNew study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-ri
- ANALYSTQiagen upgraded by Deutsche Bank with a new price targetDeutsche Bank upgraded Qiagen from Hold to Buy and set a new price target of $54.00
- PRQIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing SystemFDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndrom
- PRParse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell RecoveryNew chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a QIAGEN company (NYSE:QGEN, Frankfurt Prime Standard: QIA)), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to design large studies
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- SECSEC Form 6-K filed by Qiagen N.V.6-K - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Exceeds Q4 2025 Outlook Driven by Growth PillarsQ4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62 Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER Growth pillars on target and deliver $1.49 billion CER of sales with 8% CER growth Adjusted operating income margin at 29.5%, rises 80 basis points from 2024 despite tariffs and currency headwinds 2026 out
- PRQIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN also to showcase new automation systems: QIAsymphony Connect for clinical applications and QIAmini for accessible low-throughput sample processing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN's entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaini
- PRQIAGEN Appoints Mark Stevenson to Supervisory BoardQIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma
- ANALYSTQiagen downgraded by Deutsche Bank with a new price targetDeutsche Bank downgraded Qiagen from Buy to Hold and set a new price target of $54.00
- PRQIAGEN N.V. to Release Results for Q4 2025 and Hold WebcastQIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 3382302 To avoid waiting time, please join the even
- SECAmendment: SEC Form 25-NSE/A filed by Qiagen N.V.25-NSE/A - QIAGEN N.V. (0001015820) (Subject)
- SECSEC Form 25-NSE filed by Qiagen N.V.25-NSE - QIAGEN N.V. (0001015820) (Subject)
- SECSEC Form 6-K filed by Qiagen N.V.6-K - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 MillionReturn of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment
- ANALYSTQiagen downgraded by Citigroup with a new price targetCitigroup downgraded Qiagen from Buy to Neutral and set a new price target of $50.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- PRQIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for
- SECSEC Form 6-K filed by Qiagen N.V.6-K - QIAGEN N.V. (0001015820) (Filer)